The USA-based company is developing CD19-targeted ARTEMIS T-cell therapies under certain license agreements with the capacity to address treatment challenges for patients with blood cancers and solid tumors.

Estrella’s lead candidate, EB103, targets CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas.

In October 2022, Estrella entered into a definitive business combination agreement with TradeUP Acquisition Corp, which would make it a publicly-listed company.